LLDAS
TNFSF13B
atherosclerosis
genetic polymorphism
systemic lupus erythematosus
Journal
Biologics : targets & therapy
ISSN: 1177-5475
Titre abrégé: Biologics
Pays: New Zealand
ID NLM: 101321511
Informations de publication
Date de publication:
2024
2024
Historique:
received:
04
12
2023
accepted:
25
04
2024
medline:
8
5
2024
pubmed:
8
5
2024
entrez:
8
5
2024
Statut:
epublish
Résumé
Systemic lupus erythematosus (SLE) is a complex autoimmune disease with numerous clinical manifestations. Organ involvement can aggravate patients with SLE and cause comorbidities such as atherosclerosis. Recently, the This case-control study included 84 SLE patients, of whom 21 patients with SLE with atherosclerosis and 63 patients with SLE without atherosclerosis. Using enzyme-linked immunosorbent assay method, interleukin-6 and interferon gamma levels were quantified. The The genetic variations of The association of
Sections du résumé
Background
UNASSIGNED
Systemic lupus erythematosus (SLE) is a complex autoimmune disease with numerous clinical manifestations. Organ involvement can aggravate patients with SLE and cause comorbidities such as atherosclerosis. Recently, the
Patients and Methods
UNASSIGNED
This case-control study included 84 SLE patients, of whom 21 patients with SLE with atherosclerosis and 63 patients with SLE without atherosclerosis. Using enzyme-linked immunosorbent assay method, interleukin-6 and interferon gamma levels were quantified. The
Results
UNASSIGNED
The genetic variations of
Conclusion
UNASSIGNED
The association of
Identifiants
pubmed: 38715569
doi: 10.2147/BTT.S452792
pii: 452792
pmc: PMC11075687
doi:
Types de publication
Journal Article
Langues
eng
Pagination
95-106Informations de copyright
© 2024 Fajar et al.
Déclaration de conflit d'intérêts
The authors report no competing interest exists in this work.